This German Biotech's $6.5M Seed Round Targets a Hidden Heart Disease Driver

Jan de Vries · 2026-08-28

Here's a development that could change the game for millions living with heart disease. A new biotech player from Heidelberg, Revier Therapeutics, just hit the scene with a serious mission and the capital to back it up. They've officially launched and secured a $6.5 million Seed round to develop what they hope are the next generation of cardiometabolic therapies. It's a significant vote of confidence from a heavyweight group of investors. The round was led by the KHAN Technology Transfer Fund II, with High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg also joining in. ### The Unmet Need Driving Innovation So, what's the big deal? For all the progress in cardiovascular medicine, there's still a massive gap. Millions of patients with specific conditions—heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD)—are stuck with limited, targeted treatment options. Prof. Eva van Rooij, PhD, the company's co-founder and CEO, puts it bluntly. She says the next wave of medicines has to go deeper. We can't just treat symptoms anymore. The focus has to shift to tackling the underlying biology that actually drives the disease. That's the only way to create solutions that are both impactful and lasting for patients. Their whole mission revolves around translating a specific piece of science—class IIa HDAC inhibition—into a real pipeline of novel therapies. The goal is to get their lead programs into clinical development fast, creating value for patients and the entire healthcare system. ### A Precise Approach to a Complex Problem Revier isn't just throwing another drug candidate into the mix. They've established what they claim is the *first* therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for cardiometabolic diseases. Let's break that down without the jargon. Think of HDACs as enzymes—tiny biological machines—that play a key functional role in a host of severe diseases. Earlier attempts to target them were a bit like using a sledgehammer. They broadly hit multiple HDAC classes, which often led to nasty, dose-limiting side effects. Revier's strategy is more like using a scalpel. Their orally available small molecules are designed to be selective. They aim to inhibit only the specific, disease-driving enzymatic activity while carefully preserving healthy biological function. Prof. Johannes Backs, MD, the company's scientific founder, explains that this precision is meant to be therapeutically effective while maintaining a much better safety profile. The company is building a pipeline of these novel disease modulators, starting with HFpEF and ASCVD as their initial targets. ### Why Investors Are Betting on This Science The investor confidence speaks volumes. Michael Hamacher, PhD, of KHAN Technology Transfer Fund II, highlighted Revier's "differentiated" strategy. He believes it has the potential to finally unlock the therapeutic promise of HDAC biology, overcoming the limitations of those earlier, less precise approaches. He also pointed to the exceptional leadership team and deep scientific expertise as key factors. Combined, it creates what he sees as a unique opportunity to deliver true disease-modifying medicines and potentially reshape the standard of care. ### What's Next for the Capital? With $6.5 million in fresh capital, Revier Therapeutics has a clear plan. The funds will support: - The development of their preclinical cardiometabolic pipeline. - Advancing their lead program in HFpEF and their second program in ASCVD. - Building out their operational, scientific, and clinical teams to execute their vision. It's a classic startup story, but in one of the most challenging and impactful fields imaginable. A sharp scientific insight, a team that believes in it, and now, the resources to prove it in the real world. For professionals watching the European biotech and startup incorporation landscape, this is exactly the kind of targeted, deep-science venture that signals where the next wave of medical innovation is heading.